- cafead   Nov 28, 2022 at 07:53: PM
via The jury remains out on the prospects of anti-TIGIT checkpoint inhibitors but Gilead and Arcus Biosciences are hoping to ease concerns that the modality is a bust, teasing new phase 2 data.
article source
article source